TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06051851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125mg/m2 I.V. D1,8~1 cycle every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1.0g/m2 I.V. D1,8~1 cycle every 21 days
Study: NCT05871593

Intervention type: GENETIC
Group type: OTHER
Intervention: Molecular genetic diagnostic
Description: With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.
Study: NCT06113757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid Support Treatment
Description: The control group will only receive fluid therapy and will be monitored with the same blood parameters throughout the hospitalization.
Study: NCT05767606

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX
Description: Administration of NVX

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NVX
Description: Administration of NVX

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV20
Description: Administration of PCV20

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV20
Description: Administration of PCV20

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No intervention
Study: NCT05331157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: the efficacy of prepuncture ultrasonography to facilitate epidural block in pediatric patients undergoing elective urological operations compared with the conventional anatomical landmark technique
Study: NCT05690503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: Medication infusion intravenously over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581a
Description: Medication infusion intravenously over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581b
Description: Medication infusion intravenously over 90 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CI-581b
Description: Medication infusion intravenously over 90 minutes.
Study: NCT05136118

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAPB
Description: TAPB will be given to parturients whether by the modified surgeon assisted approach or by the ultra-sound guided approach.
Study: NCT06307782

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: whey protein intake before surgery
Description: Total Hip Arthroplasty whey protein intake,Total Hip Arthroplasty, whey protein intake,CRP,cortisol insulin resistance

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Water before surgery
Description: Total Hip Arthroplasty water before surgery,Total Hip Arthroplasty, water intake,CRP,cortisol insulin resistance
Study: NCT05134896

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spatial light modulator
Description: This device compensates for the eye's optical imperfections (aberrations) at the foveal and peripheral retina.
Study: NCT05203718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Response Training (FRT)
Description: All patients will complete the 12-week FRT intervention consisting of one in-person session (during the baseline visit) and three weekly sessions at home, one delivered via video conference (WebEx) and two self-guided. Food Response Training (FRT) is a computer-based attention bias modification intervention. The intervention will be delivered on a computer or smart device (e.g. iPhone). Patients will use the FoodTrainer application available for Android and iPhone (https://www.exeter.ac.uk/foodt/about/).
Study: NCT04662411

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: acute intake of 0 mg butyrate and hexanoate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 1
Description: acute intake of 650 mg butyrate and hexanoate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 2
Description: acute intake of 1325 mg butyrate and hexanoate

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: butyrate and hexanoate amount 3
Description: acute intake of 2000 mg butyrate and hexanoate
Study: NCT04992039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO HEARTS technical package
Description: Components of WHO HEARTS technical package are~1. Universal BP screening via A\&D arm-in BP device.~2. Training of Medical Officers and Nurses on BP measurement using standard techniques.~3. Training of the nurses on screening, registration data collection via the Simple mobile smart-phone digital clinical hypertension information application.~4. Use of a drug and dose specific hypertension treatment protocol.~5. Standardized inventory and procurement practice to ensure a reliable supply of protocol medications.~6. Training and support for team-based model of hypertension care delivery.~7. Access to the Simple data dashboard for program monitoring.~8. Standardized procedure for patient follow-up.~9. Community-based prescription refilling.
Study: NCT05810844

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Motor Relearning Program (MRP)
Description: MRP technique with a conventional physiotherapy treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuro Development Treatment (NDT)
Description: Neuro-Development Treatment NDT as well as conventional treatment. Conventional physiotherapy treatment will help to reduce the functional impairments in chronic ischemic stroke patients
Study: NCT04735965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine would be intravenously infused at a dose of 1μg/kg over 15 minutes 30 min before the end of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Meperidine would be intravenously injected at a dose of 0.5mg/kg 30 min before the end of surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placeb
Description: Equal volume of normal saline to dexmedetomidine and meperidine group.
Study: NCT05491655

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: High Intensity His Bundle pacing
Description: All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Intensity His Bundle pacing
Description: All patients will be implanted with an Implantable cardioverter defibrillator (ICD) and an ICD lead in the right ventricle (either RV apex or RV septum). In all patients a pacing lead will be positioned in the right atrium (typically the right atrial appendage). All patients will have a pacemaker lead positioned on the His bundle to obtain direct His-bundle capture.
Study: NCT06141655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Description: Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
Study: NCT06190535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etamsylate
Description: Enteral administration of Etamsylate as solution galenic form
Study: NCT04666714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praga formulation
Description: Praga formulation tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo pregabalin 75mg
Description: Placebo pregabalin 75mg tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Pregabalin 150mg
Description: Placebo Pregabalin 150mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 75mg
Description: Pregabalin 75mg tablet
Study: NCT06141655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Influenza vaccine
Description: Participants will be individually randomized 1:1 to receive either QIV-HD or QIV-SD, one dose, the day of the inclusion in the trial
Study: NCT06163560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone app Happy Baby HK
Description: Happy Baby HK will provide developmental stage, developmental aspects, parenting videos and cartoon images created for new mothers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Family Health Service parenting booklet
Description: The parenting booklet is publicly available and provides brief caretaking tips for mothers with children under 3 years of age.
Study: NCT05508243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic Nasal Spray
Description: Health care product - nasal application
Study: NCT05998252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alveo HP Balloon Dilatation Catheter
Description: Alveo HP Balloon is intended for dilatation of stenosis in the coronary artery.
Study: NCT05843708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 40 mg Oral Tablet
Description: Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 40 mg Oral Tablet
Description: Single oral dose of 1×40 mg vorasidenib tablet administered :~* under fasted conditions (all subjects will fast overnight for at least 10 hours prior to dosing and for at least 4 hours after dosing.~* or following a low fat meal (approximatively 400 to 500 calories) (Substudy A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg Oral Tablet
Description: Twice daily (morning and evening) oral doses of ciprofloxacin 1×500 mg tablet on Days 1 through 14 (Substudy B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 10 mg Oral Tablet
Description: Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorasidenib 10 mg Oral Tablet
Description: Single oral dose of vorasidenib 2×10 mg tablets administered on Day 1 (Substudy B)
Study: NCT05074069

Intervention type: PROCEDURE
Intervention: Gynaecological reconstruction
Description: Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation

Intervention type: PROCEDURE
Intervention: Gynaecological reconstruction
Description: Methods of vulvovaginal reconstruction, e.g. flap formation, neovagina formation
Study: NCT04701866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music will be provided via headphones during all 6 ketamine treatments, beginning at the commencement of each infusion and ending 55 minutes later. On the day of each infusion, before the treatment begins, clinicians will discuss music choices with participants in order to select amongst one of several options that have been designed for this purpose (length, genre, intensity, etc.).
Study: NCT06514027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsules
Description: BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsules
Description: BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsules
Description: BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEBT-109 Capsules
Description: BEBT-109 Capsules: Administration and Dosage: Oral administration, 120mg or 180mg; Frequency and Duration of Administration: Once a day or twice a day,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium for Injection
Description: Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium for Injection
Description: Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium for Injection
Description: Pemetrexed Disodium for Injection: Administration and Dosage: Intravenous infusion, 500mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle,and 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Study: NCT04666714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Praga formulation
Description: Placebo Praga formulation tablet
Study: NCT05467046

Intervention type: DEVICE
Intervention: Smartwatch system
Description: The Atopic Dermatitis patient cohort is exposed to using a smartwatch system for 5 weeks.
Study: NCT04831372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Off Table Group
Description: Total Hip arthroplasty being performed via the Direct Anterior Approach using a standard operating room table

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On Table Group
Description: Total Hip arthroplasty being performed via the Direct Anterior Approach using a traction table
Study: NCT06514027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin Injection
Description: Carboplatin Injection: Administration and Dosage: Intravenous infusion, AUC=5 mg/ml.min, with a single dose not exceeding 800 mg; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin Injection
Description: Cisplatin Injection: Administration and Dosage: Intravenous infusion, 75 mg/m\^2; Frequency and Duration of Administration: On the first day of each cycle for the first four cycles, and 21 days as a treatment cycle, totaling four cycles.
Study: NCT06514482

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Diagnosis

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis
Description: Diagnosis
Study: NCT05654766

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Parameters such as FSC, SSC, median fluorescence of anti CD42b, PAC-1, CD41, CD63, CD62P, as well as Annexin V fluorescence will be assessed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation and plasma coagulation
Description: Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).

Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet aggregation and plasma coagulation
Description: Turbodimetric platelet aggregation test, impedance platelet aggregation test. Standard plasma coagulation test (fibrinogen level, prothrombin test, thrombin time, activated partial thromboplastin time (aPTT)).
Study: NCT05329779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brexanolone
Description: Brexanolone is a derivative of allopregnanolone, which is FDA-approved to treat postpartum depression.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo is a 0.45% sodium chloride infusion.
Study: NCT05123742

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Testing
Description: Testing for the SARS-CoV-2 virus

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 Testing
Description: Testing for the SARS-CoV-2 virus
Study: NCT05833685

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT06089161

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants in this group will receive standard of care treatment for sleep apnea.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Participants in this group will receive standard of care treatment for sleep apnea.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized OSA Treatment
Description: Participants in this group will receive standard of care treatment plus the personalized treatment that consists of videos approximately three minutes long, virtual, accessed through web based application, that the participant watches weekly. The purpose of the video is tailored educational content for sleep apnea.
Study: NCT04859842

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulse Electromagnetic Field
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with PEMF in prone position. Each session will be 45 minute long with a 15 minute PEMF therapy and a 30 minute conventional therapy program.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with Interferential current in prone position. Four interferential electrode will be placed on low back region. Each session will be 45 minute long with a 15 minute interferential current and a 30 minute conventional therapy program.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Patients will be treated for two weeks, five days a week, one session a day, and 10 sessions with conventional therapy and sham electrotherapy. Sham application will be performed on prone position with four electrodes and electrodes will stay for 15 minutes on this region.
Study: NCT04998019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PositiveLinks
Description: The PositiveLinks (PL) patient mobile app delivers appointment reminders, daily queries (check-ins) of mood, stress and medication adherence, tailored educational resources, access to the PL team for individualized assistance, and the opportunity to interact with other users on a secure, anonymous community message board (CMB).
Study: NCT05748730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCHART
Description: The Safety Planning App will guide primary care providers or mental health clinicians in the use of an emotion regulation and safety planning app (BRITE) to be loaded on the phone of depressed and suicidal adolescents in order to improve depression and reduce the likelihood of a suicide attempt.~The Mental Health Screener is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.~The Text Messages is a personalized text messaging intervention for patients and parents that targets engagement with the safety plan to increase the likelihood that a depressed or suicidal patient will maintain or initiate recommended services.~Participants will receive usual care at their pediatric primary care practice following screening including information, psychoeducation, and referral to a mental health treatment provider.
Study: NCT05823168

Intervention type: DRUG
Intervention: Antiepileptic Drug
Description: we osberve the efficacy of antiepileptic drungs on preventing seizures and their impact on rehabilitation outcome
Study: NCT05748730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Participants in this group will receive usual care from their primary care provider or mental health care provider which may include development of a paper safety plan.
Study: NCT05562115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tear collection
Description: Collection of tears by Schirmer strip (2 to 4 mm).